AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Medicines Agency's (EMA) Committee for ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and ...

EU recommends approval of AstraZeneca & Daiichi Sankyo’s Enhertu for patients with previously treated HER2-positive metastatic solid tumours: Cambridge, UK Monday, May 25, 2026, ...

Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

The phase 3 DESTINY-Breast05 trial showed patients treated with ENHERTU had a three-year invasive disease-free survival rate of 92.4% versus 83.7% for those receiving T-DM1 as a post-neoadjuvant ...

Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial. Two new indications bring Daiichi Sankyo and ...

Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer ...

PITTSBURGH, Pa. (Ivanhoe Newswire) - One in eight women will be diagnosed with breast cancer in their lifetime - the second leading cause of cancer death for women, behind lung cancer but after years ...